N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.

N-Substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines (6a-g) were designed and synthesized as conformationally constrained analogues of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (4) class of opioid receptor pure antagonists. The methyloctahydroisoquinolines 6a-g can exist in conformations where the 3-hydroxyphenyl substituent is either axial or equatorial, similar to the (3-hydroxyphenyl)piperidines 4. The 3-hydroxyphenyl equatorial conformation is responsible for the antagonist activity observed in the (3-hydroxyphenyl)piperidine antagonists. Single-crystal X-ray analysis of 6a shows that the 3-hydroxyphenyl equatorial conformation is favored in the solid state. Molecular modeling studies also suggest that the equatorial conformation has lower potential energy relative to that of the axial conformation. Evaluation of 6a-g in the [(35)S]GTP-gamma-S in vitro functional assay showed that they were opioid receptor pure antagonists. N-[4a-(3-Hydroxyphenyl)-8a-methyl-2-(3-phenylpropyl)octahydroisoquinoline-6-yl]-3-(piperidin-1-yl)propionamide (6d) with a K(e) of 0.27 nM at the kappa opioid receptor with 154- and 46-fold selectivity relative to those of the micro and delta receptors, respectively, possessed the best combination of kappa potency and selectivity.

• Publication year

  2005

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2005-12-29

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM058261CPMID 16366600PMCID PMC2585695
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of the first N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activity.

  2004cited by this paper
• Discovery of the First N-Substituted 4β-Methyl-5-(3-hydroxyphenyl)morphan To Possess Highly Potent and Selective Opioid δ Receptor Antagonist Activity

  2004cited by this paper
• Pharmacological properties of JDTic: a novel κ-opioid receptor antagonist

  2004cited by this paper
• Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

  2004cited by this paper
• Probes for Narcotic Receptor Mediated Phenomena

  2003cited by this paper
• Na+-dependent high affinity binding of [3H]LY515300, a 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid receptor inverse agonist.

  2003cited by this paper
• Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.

  2003cited by this paper
• Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphans.

  2002influential reference
• Pharmacotherapy of addictions

  2002cited by this paper
• Probes for narcotic receptor mediated phenomena. Part 28: new opioid antagonists from enantiomeric analogues of 5-(3-hydroxyphenyl)-N-phenylethylmorphan.

  2002cited by this paper
• Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.

  2001cited by this paper
• Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.

  2001cited by this paper
• Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.

  2000cited by this paper
• 5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist.

  2000influential reference
• Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.

  1998cited by this paper
• N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.

  1998cited by this paper
• Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors.

  1998cited by this paper
• Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.

  1998cited by this paper
• BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY

  1996cited by this paper
• Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders.

  1994influential reference
• Structure-activity relationships of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for mu- and kappa-opioid receptors.

  1993cited by this paper
• 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.

  1993cited by this paper
• Stereochemical studies of the 4‐alkyl‐4‐arylpiperidine class of opioid ligand

  1989influential reference
• Stereochemical influences upon the opioid ligand activities of 4-alkyl-4-arylpiperidine derivatives.

  1989influential reference
• Synthesis and analgesic properties of N-substituted trans-4a-aryldecahydroisoquinolines.

  1988cited by this paper
• Hexahydro-1H-1-pyrindines from acid rearrangement of 9-alkylidene-5-(m-methoxyphenyl)-2-methylmorphans. A new structural type of narcotic antagonists.

  1987cited by this paper
• Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.

  1987cited by this paper
• Medicinal chemistry : a biochemical approach

  1985cited by this paper
• Racemic and optically active 2,9-dimethyl-5-(m-hydroxyphenyl)morphans and pharmacological comparison with the 9-demethyl homologues.

  1984cited by this paper
• Different receptor sites mediate opioid agonism and antagonism.

  1983cited by this paper
• New structural concepts for narcotic antagonists defined in a 4-phenylpiperidine series

  1978cited by this paper

• Unified Enantioselective Synthesis of 5-Phenylmorphans and cis-Octahydroisoquinolines.

  2025cites this paper
• Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine

  2022cites this paper
• Eight-Membered Rings With Two Heteroatoms 1,3

  2021cites this paper
• Highly Diastereo‐ and Enantioselective Cascade Synthesis of Bicyclic Lactams in One‐Pot

  2018cites this paper
• Design, Synthesis, and Biological Evaluation of Structurally Rigid Analogues of 4-(3-Hydroxyphenyl)piperidine Opioid Receptor Antagonists.

  2016cites this paper
• Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of replacement of the 3-hydroxyphenyl group with pyridine or thiophene bioisosteres.

  2016cites this paper
• 4β-Methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonist.

  2013cites this paper
• Design and Synthesis of Novel Opioid Ligands and Their Pharmacologies

  2012cites this paper
• Synthesis of new opioid derivatives with a propellane skeleton and their pharmacology: part 1.

  2011cites this paper
• Phosphorylation of the μ-Opioid Receptor at Tyrosine 166 (Tyr3.51) in the DRY Motif Reduces Agonist Efficacy

  2010cites this paper
• Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents

  2010cites this paper
• Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity.

  2010cites this paper
• Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).

  2009cites this paper
• Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).

  2008cites this paper
• Intramolecular 1,5-hydrogen atom transfer reaction promoted by phosphoramidyl and carbamoyl radicals: synthesis of 2-amino-C-glycosides

  2007cites this paper
• N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists.

  2006cites this paper
• Endogenous opiates and behavior: 2005.

  2006cites this paper